Shares of Omeros (OMER), which had been halted ahead of the company announcing FDA approval of YARTEMLE for treatment of TA-TMA, is scheduled to resume trading at 9:50 am ET, with quotation to resume at 9:45 am ET, according to Nasdaq.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER: